Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 13/20 | 0.41 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 4/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 4/20 | 0.37 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.37 |
| ▸ | AADAC | P22760 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25464785 | 0.87 | MEN1 (0.42) | EPHX2SSTR4HPGDSMCHR1 | |
| SCHEMBL25460886 | 0.82 | TRPV1 (0.36) | EPHX2L3MBTL1RAF1 | |
| SCHEMBL25464788 | 0.82 | TACR1 (0.42) | SSTR4MCHR1 | |
| SCHEMBL25464778 | 0.80 | CNR1 (0.36) | SSTR4 | |
| SCHEMBL25464147 | 0.79 | PDK1 (0.44) | EPHX2SSTR4EPHX1 | |
| SCHEMBL25464763 | 0.79 | CACNA1B (0.38) | EPHX2SSTR4 | |
| SCHEMBL30059779 | 0.78 | ALOX5 (0.38) | EPHX2L3MBTL1 | |
| SCHEMBL25170201 | 0.78 | ALOX5 (0.38) | EPHX2L3MBTL1 | |
| SCHEMBL25460726 | 0.78 | AKR1C3 (0.40) | EPHX2 | |
| SCHEMBL30057746 | 0.78 | AKR1C3 (0.40) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151074-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151074-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | GIPR, GLP1R, GCGR | EPHX2 3721/4885SSTR4 82/4885HPGDS 2374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.